Introduction:
Transplant renal artery stenosis (TRAS) is a potentially curable cause of post-transplant arterial hypertension and allograft dysfunction. We investigated the incidence, clinical presentation, and outcome of TRAS in renal allograft recipients.
Methods:
We conducted a retrospective analysis of the medical records of patients who have received renal transplants at Zydus Hospital since 2020 and are currently under regular follow-up care. A total of 261 renal transplant recipients were included in the study. We examined demographic information, types of renal donors, and post-transplant evaluations including blood pressure, graft function, and rejection episodes. Additionally, we analyzed laboratory and investigative data, such as renal function tests, Doppler imaging of the transplant renal artery, and angiograms.
Results:
11 out of 261 patients had transplant renal artery stenosis (TRAS), with an incidence of 4.21%. Among them, 209 patients had living donors and 52 had cadaveric donors. The incidence of TRAS following live donor transplantation was 0.96%, while for deceased donors it was 17.3%. The median time to develop TRAS was 3 months 12 days (range 1-17 months). Out of 11, 9 patients (81.8%) presented with accelerated hypertension; 2 (18.2%) patients developed allograft dysfunction with accelerated hypertension. Out of 11 patients with TRAS, 9 patients had a history of Hypertension; 3 had Diabetes and 2 had simultaneous liver kidney transplants. All patients were treated with percutaneous transluminal angioplasty with stenting, and none of them had recurrent TRAS.
Conclusions:
The overall incidence of TRAS in the study was 4.21%. TRAS developed more commonly in cadaveric transplantation and commonly developed 3 months after transplantation. Early detection and correction reduce patients’ morbidity and allograft dysfunction.
I have no potential conflict of interest to disclose.
I did not use generative AI and AI-assisted technologies in the writing process.